Sanofi ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $54.34
- Today's High:
- $54.845
- Open Price:
- $54.79
- 52W Low:
- $35.5199
- 52W High:
- $55.6421
- Prev. Close:
- $54.47
- Volume:
- 1684380
Company Statistics
- Market Cap.:
- $136.57 billion
- Book Value:
- 29.017
- Revenue TTM:
- $46.04 billion
- Operating Margin TTM:
- 23.87%
- Gross Profit TTM:
- $31.70 billion
- Profit Margin:
- 18.71%
- Return on Assets TTM:
- 5.56%
- Return on Equity TTM:
- 12.07%
Company Profile
Sanofi ADR had its IPO on 2002-07-01 under the ticker symbol SNY.
The company operates in the Healthcare sector and Drug Manufacturers-General industry. Sanofi ADR has a staff strength of 91,573 employees.
Stock update
Shares of Sanofi ADR opened at $54.79 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $54.34 - $54.85, and closed at $54.68.
This is a +0.39% increase from the previous day's closing price.
A total volume of 1,684,380 shares were traded at the close of the day’s session.
In the last one week, shares of Sanofi ADR have increased by +2.92%.
Sanofi ADR's Key Ratios
Sanofi ADR has a market cap of $136.57 billion, indicating a price to book ratio of 1.6254 and a price to sales ratio of 2.6884.
In the last 12-months Sanofi ADR’s revenue was $46.04 billion with a gross profit of $31.70 billion and an EBITDA of $14.05 billion. The EBITDA ratio measures Sanofi ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Sanofi ADR’s operating margin was 23.87% while its return on assets stood at 5.56% with a return of equity of 12.07%.
In Q2, Sanofi ADR’s quarterly earnings growth was a positive 21.7% while revenue growth was a negative 1.4%.
Sanofi ADR’s PE and PEG Ratio
- Forward PE
- 10.4932
- Trailing PE
- 14.842
- PEG
- 1.6501
Its diluted EPS in the last 12-months stands at $3.67 per share while it has a forward price to earnings multiple of 10.4932 and a PEG multiple of 1.6501. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Sanofi ADR’s profitability.
Sanofi ADR stock is trading at a EV to sales ratio of 3.0525 and a EV to EBITDA ratio of 13.5753. Its price to sales ratio in the trailing 12-months stood at 2.6884.
Sanofi ADR stock pays annual dividends of $3.56 per share, indicating a yield of 3.55% and a payout ratio of 42.99%.
Balance sheet and cash flow metrics
- Total Assets
- $125.35 billion
- Total Liabilities
- $24.80 billion
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 42.99%
Sanofi ADR ended 2024 with $125.35 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $125.35 billion while shareholder equity stood at $72.63 billion.
Sanofi ADR ended 2024 with $0 in deferred long-term liabilities, $24.80 billion in other current liabilities, in common stock, $0 in retained earnings and $0 in goodwill. Its cash balance stood at $7.99 billion and cash and short-term investments were $7.99 billion. The company’s total short-term debt was $4,947,000,000 while long-term debt stood at $14.24 billion.
Sanofi ADR’s total current assets stands at $30.24 billion while long-term investments were $9.51 billion and short-term investments were $0. Its net receivables were $353.00 million compared to accounts payable of $19.28 billion and inventory worth $21.63 billion.
In 2024, Sanofi ADR's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Sanofi ADR paid $0.43 in dividends in 2024.
Other key metrics
- Current Trading Price
- $54.68
- 52-Week High
- $55.6421
- 52-Week Low
- $35.5199
- Analyst Target Price
- $64.13
Sanofi ADR stock is currently trading at $54.68 per share. It touched a 52-week high of $55.6421 and a 52-week low of $55.6421. Analysts tracking the stock have a 12-month average target price of $64.13.
Its 50-day moving average was $53.1 and 200-day moving average was $49.93 The short ratio stood at 2.4 indicating a short percent outstanding of 0%.
Around 0.6% of the company’s stock are held by insiders while 1063.3% are held by institutions.
Frequently Asked Questions About Sanofi ADR
Similar Industry Stocks (Drug Manufacturers-General)
Most Active
Top Gainers
Top Losers
About
Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as dupixent, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers body lotions, anti-itch products, moisturizing and soothing lotions, body and foot creams, and eczema powders. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for Parkinson’s disease; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Amunix Pharmaceuticals, Inc for T-cell engagers and cytokine therapies. It also enters in a strategic collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.